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ABSTRACT 
 
Background: The purpose of this study is to evaluate whether demographics, lifestyle habits, 
clinical data and alcohol dehydrogenase polymorphisms rs1229984 and rs1573496 associated with 
first primary head and neck (HNC) are associated with overall survival, recurrence, and second 
primary cancer (SPC).  
Methods: We conducted a follow-up study in five centres including 801 cases. Hazard ratios (HRs) 
and 95% confidence intervals (CIs) were estimated for overall survival, recurrence and SPC. 
Results: Five-years overall survival was 62% for HNC cases, 55% for oral cavity, 53% for 
oropharynx, 41% for hypopharynx, and 71% for larynx. Predictors of survival were older ages (HR 
= 1.18 for 5 years increase; CI: 1.07–1.30), higher tumour stage (HR = 4.16; CI: 2.49–6.96), and 
high alcohol consumption (HR = 3.93; CI: 1.79–8.63). A combined therapy (HR = 3.29; CI: 1.18–
9.13) was associated with a worst prognosis for oral cavity cancer. The only predictor was higher 
tumour stage (HR = 2.25; CI: 1.26–4.03) for recurrence, and duration of smoking (HR = 1.91; CI: 
1.00–3.68) for SPC. ADH1B rs1229984 polymorphism HRs for HNC and oesophageal cancer death 
and for alcohol related cancer death were 0.67 (95% CI: 0.42–1.08), and 0.64 (95% CI: 0.40–1.03), 
respectively. 
Conclusions: The survival expectation differs among HNC sites. Increasing age and stage, and high 
alcohol consumption were unfavourable predictors of HNC survival overall. Duration of tobacco 
consumption before the first primary tumour was a risk factor for SPC. 
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1. Introduction 
 
Cancers of the head and neck (HNC) are the sixth most common cancer worldwide, with more than 
half a million new cases and over 450,000 deaths in 2012 [1]. These malignancies include cancers 
of the oral cavity, oropharynx, hypopharynx, and larynx, and 90% are squamous cell carcinomas [2]. 
Tobacco smoking and alcohol consumption are the predominant risk factors for HNC [3,4], with 
human papillomavirus (HPV) infection (for oropharynx), diet, physical activity, and nutrition also 
playing an important role [5–7]. A family history of HNCs in first degree relatives increases the risk 
of HNCs [8,9], indicating that genetic factors might be involved in the pathogenesis of HNC. 
Polymorphisms in genes encoding for metabolism of alcohol to acetaldehyde [alcohol 
dehydrogenase gene family (ADH)] and from acetaldehyde to acetate [aldehyde dehydrogenase 2 
(ALDH2)], and CYP2E1 polymorphisms, are suspect in HNC and other alcohol-related cancer 
aetiology [10–19]. In particular, a significant protective effect of two single nucleotide 
polymorphisms (SNPs) towards upper aero-digestive tract cancer (UADT) was reported for two 
alcohol dehydrogenase genes: ADH1B (rs1229984) and ADH7 (rs1573496) [20]. 
In Europe, the 5-year survival rate varies considerably according to anatomic site, 63.1% for cancer 
of the larynx, 48.5% for oral cavity, 39.8% for oropharynx and 25.5% for hypopharynx cancer [21]. 
About 40–60% of HNC patients develop recurrences, and around 20% of HNCs develop second 
primary cancer (SPC), both being associated with poorer survival [22]. 
Despite various therapeutic interventions, including surgery, radiotherapy, and chemotherapy, the 5-
year survival rate for this disease has improved only marginally during the past two decades. For 
patients with disease confined to the head and neck, there are two  major  and  distinct  patterns  of  
treatment  failures  after definitive therapy: recurrence of primary disease (local, regional or distant) 
and development of SPC [23,24]. The 5-year survival rate after SPC diagnosis is about 8% if the 
malignancy is outside the head and neck area, and increased to 30% if the SPC is an HNC [25]. So 
far, few studies examined the prognostic significance of gene polymorphisms in alcohol metabolism 
and oxidative stress-related genes in patients with HNC, and they reported evidence of an 
association of specific polymorphisms with survival (CYP2E1, ADH3) or higher recurrence 
(CYP1A2) [14,15,26]. The purpose of our study is to evaluate whether two specific alcohol 
dehydrogenase genes [ADH1B  (rs1229984) and ADH7  (rs1573496)], and established 
demographics and lifestyle-related risk factors for HNC, influence overall survival, recurrence, and 
development of SPC in HNC patients. To explore these issues we conducted a multicentre follow-
up study in Italy, including five Italian centres totalling 801 HNC cases. 
 
 
2. Materials and methods 
 
Subjects with histologically confirmed primary squamous cell carcinoma of the head and neck were 
included. Participants were drawn from five Italian centres located in different regions, that are 
members of the International Head and Neck Cancer Epidemiology (INHANCE) Consortium [27]. 
The centres are located in: Aviano (Friuli Venezia Giulia), Milan (Lombardy), Padua (Veneto), 
Rome (Latium), and Turin (Piedmont). The Aviano, Padua and Turin centre are the Italian centres 
of the European ARCAGE case–control study on HNC cancer [28]. 
The study was approved by the local Ethical Committees at each participating centre. HNC tumours 
were classified into anatomic site according to the following ICD-O-2 categories: oral cavity (codes 
C00.3–C00.9, C02.0–C02.3, C03.0, C03.1, C03.9, C04.0, C04.1, C04.8, C04.9, C05.0, C06.0–
C06.2, C06.8, and C06.9), oropharynx (codes C01.9, C02.4, C05.1, C05.2, C09.0, C09.1, C09.8, 
C09.9, C10.0–C10.4, C10.8, and C10.9), hypopharynx (codes C12.9, C13.0–C13.2, C13.8, and 
C13.9), oral cavity or pharynx overlapping or not otherwise specified (codes C02.8, C02.9, C05.8, 
C05.9, C14.0, C14.2, and C14.8), larynx (codes C32.0–C32.3 and C32.8–C32.9). The tumours were 
staged according tumour, node, metastasis (TNM) classification [29]. 
The recruitment was conducted from 2002 to 2005 in Aviano, Padua, and Turin, while from 2001 to 
2009 in Milan and from 2002 to 2012 in Rome. The participation rates ranged across centres from 
88% in Turin to 98% in Rome. 
 
2.1 Data collection 
 
Patients were interviewed face-to-face in all centres by trained interviewers or medical doctors, on 
demographics, alcohol and tobacco consumption, and other relevant lifestyle factors. Health 
behaviours questions focused on the time period ending 1 year prior to diagnosis. 
Participants were also followed from the date of diagnosis to the date of death, end of follow-up at 
June 30, 2013, or loss to follow-up, whichever occurred first. Death certificate data were also used 
for mortality, and the cause of death was coded according to the International Classification of 
Diseases, Ninth Revision. Cancer recurrence and SPC were collected for from medical records and 
cancer registries. Data on tumour pathology and treatment were obtained from pathology records. 
Only the centre of Milan did not have active follow-up of cancer cases and medical records were 
not used as source of information for recurrence and SPC. 
Standard data collection forms were used by all the centres to collect the aforementioned 
information. Data from individual centres were received from the coordinating centre at the 
Universita` Cattolica del Sacro Cuore in Rome. All data were checked for internal consistency and 
clarifications were requested from the original investigators when needed. 
 
2.2. Genotyping 
 
The genotyping of the European ARCAGE and Rome studies was conducted using Illumina Sentrix 
HumanHap300 BeadChip at the Centre d’Etude du Polymorphisme Humain, as described 
previously [30]. Quality control for each genotyping was performed in each experiment, and 10% of 
the total samples were randomly selected and retested with 100% concordance. 
The genotyping of the Milan study of the two SNPs rs1229984 (ADH1B) and rs1573496 (ADH7) 
was performed by Applied Biosystems TaqMan Drug Metabolism Genotyping Assay at the 
coordinating centre. DNA was extracted from peripheral blood lymphocytes. 
 
2.3. Outcomes definition 
 
The primary endpoint was overall survival (OS), measured as the time from the date of initial 
diagnosis of index primary tumours to the date of death from any cause. All observations were 
censored at loss to follow-up and at the end of the study period. 
Recurrence was defined as the local, regional or distant return of cancer after that the patient was 
defined as disease free. 
By definition, a second primary tumour of the same histologic type as the first had to be separated 
from it by more than 2 cm of normal epithelium or had to occur at least 3 years after diagnosis of 
the first primary tumour. Any new tumour of a different histologic type was characterized as a 
second primary tumour without the requirement of a separation of more than 2 cm [31]. 
We defined alcohol-related cancers as those for which the International Agency for Research on 
Cancer (IARC) has concluded there is sufficient evidence of carcinogenicity in human beings in 
relation to active alcohol drinking [32]: oral cavity, pharynx, larynx, oesophagus, and liver, and, 
additionally breast cancer and colorectal cancer. 
 
2.4. Statistical analysis 
 
We used the Kaplan–Meier method to calculate the cumulative proportion surviving and to plot the 
survival curves. We used the multivariable Cox’s proportional hazards model to determine 
independent predictors of OS, recurrence and SPC. We formally tested the Cox proportional 
hazards assumption for each covariate using Schoenfeld residuals [33]. Hazard ratios (HR) for all-
cause mortality were adjusted for age at diagnosis, gender, tumour stage, and comorbidity. In the 
multivariable analysis, we also excluded all cases from Milan centre because information on tumour 
stage was not available. 
Models to predict SPC were adjusted for age at diagnosis and tumour stage. The association 
between SNPs and various outcomes was explored using univariate analysis. 
With respect to smoking, patients were classified as never, former, or current smokers. Cumulative 
tobacco consumption was calculated as intensity of smoking (never smokers, ≤ 20 cigarettes/day, 
>20 cigarettes/day), and smoking duration in years (never smokers, ≤ 20, 21–40, >40). With respect 
to alcohol drinking, 
subjects were classified as never drinkers, former and current, and according to alcohol 
consumption (none or <1 drink equivalent/ day, 1–2 drinks/day, >2 drinks/day). The standard 
definition for one drink equivalent was 14 g ethanol, which approximately corresponds to 150 mL 
wine, 330 mL beer, and 36 mL spirits [32]. 
The genotypes of rs1229984 and rs1573496 were dichotomized according to presence versus 
absence of the minor allele. 
Analyses were performed for overall HNC and for individual subsites (oral cavity, oropharynx, 
hypopharynx, larynx) where possible. Statistical analyses were performed using Stata software, 
version 13 (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp 
LP). 
 
3. Results 
 
A total of 801 subjects were included in the study from the five Italian centres (Table 1). Disease 
location was oral cavity in 191 (23.8%) patients, oropharynx in 139 (17.4%), hypopharynx in 43 
(5.4%), and larynx in 398 (49.7%). For the remaining 30 patients (3.7%), the disease location was 
oral cavity or pharynx not otherwise specified. 
 
3.1. Overall survival 
 
There were 164 (20.5%) women and 637 (79.5%) men, with a median age at diagnosis of 62 (range: 
27–88) years. Median follow-up time since cancer diagnosis was 59 months (interquartile range: 
20–92). During the follow-up, 358 of 801 cases (40.6%) had died, of which 227 (63.4%) died from 
HNC and oesophageal cancer and 49 (13.7%) from other cancers. Five-years overall survival for all 
HNC sites combined was 62% (IQ range 59–66%): oral cavity 55% (IQR 47–62%), oropharynx 
53% (IQR 44–61%), hypopharynx 41% (IQR 26–56%), and larynx 71% (IQR 66–76%). Median 
survival time in months was higher for laryngeal cancer than for the other tumour sites [63 months 
versus 53 (oral cavity p = 0.006), 49 (oropharynx p = 0.001), 50 (hypopharynx p = 0.125)] (Fig. 1). 
Table 2 presents the distribution for selected covariates and the HR for all-cause mortality adjusted 
by age at diagnosis, gender, tumour stage, and comorbidity by HNC sites and combined. A reduced 
survival was associated with increasing age, with an HR of 1.18 (95% CI: 1.07–1.30) for all HNC 
sites for every 5-years increase. Results were still significant when stratified according to HNC sites, 
except for oropharynx. 
A tumour stage IV was a negative prognostic factor for cancer of oral cavity (HR = 3.34; 95% CI: 
1.30–8.59) and larynx (HR = 4.19; 95% CI: 1.93–9.10). For all HNC combined, the HR was 1.94 
(95% CI: 1.10–3.43) for stage II patients, 2.89 (95% CI: 1.62–5.14) for stage III patients, and 4.16 
(95% CI: 2.49–6.96) for stage IV patients. 
A combined therapy including radiotherapy plus surgical treatment and chemotherapy was a 
negative prognostic factor for cancer of oral cavity (HR = 3.29; 95% CI: 1.18–9.13). 
In univariate analysis only, cigarette smoking was a negative prognostic factor for those current 
smokers before diagnosis of oral cavity cancer (HR = 1.78; 95% CI: 1.05–3.03) compared to never 
smokers. The death rate among subjects who had smoked more than 40 years, was significantly 
higher in patients with oral cavity (HR = 2.26; 95% CI: 1.25–4.07) and oropharynx tumour (HR = 
2.38; 95% CI: 1.11–5.11), as well as in patients with HNC in general (HR = 1.54; 95% CI: 1.09–
2.17). However, these patterns did not persist after adjustment for significant prognostic factors. 
Excessive alcohol use was associated with an increased hazard of all-cause deaths when we 
considered all HNC sites (1-2 drinks per day, HR = 2.83; 95% CI: 1.30–6.16; >2 drinks per day, 
HR = 3.93; 95% CI: 1.79–8.63). 
 
 
 
3.2. Cancer recurrence 
 
Among the 771 HNC patients included (30 patients with cancer of the oral cavity or pharynx not 
otherwise specified were excluded), disease recurrence was unknown for 132 subjects (17.1%) and 
additional 53 (6.8%) subjects did not reported the date of recurrence, thus leaving 586 (76.0%) 
eligible patients with complete information on recurrence. A total of 149 (25.4%) patients with 
recurrence were included in the analysis. Demographic, clinical, and lifestyle characteristics and the 
association with recurrence are reported in Table 3. The risk of recurrence was associated with the 
highest stage for HNC (HR = 2.25, 95% CI 1.26–4.03). No significant association was reported for 
alcohol drinking and smoking habits (Table 3). 
 
3.3. Second primary cancer 
 
Information on SPC was available for 613 (79.5%) patients. Among them, 117 (19%) developed a 
SPC during follow-up period. The most frequent SPC sites were HNC (32.7%) and lung (27.7%) 
(data not shown). The risk for developing SPC increased with increasing years of smoking. Taking 
never smoking as the reference, the HR for developing SPC was 1.91 (95% CI: 1.00– 3.68) in 
patients who smoked more than 40 years. By restricting the analysis to second primary alcohol 
related and smoke related cancers, results did not change (data not shown). 
 
3.4. ADH1B (rs1229984) and ADH7 (rs1573496) 
 
Genotyping data on ADH1B and ADH7 SNPs was available for 702 (91%) subjects, and their 
association with prognosis is reported in Table 4. In unadjusted analyses, the HRs for ADH1B 
rs1229984, though not statistically significant, were suggestive of differences in risk for HNC and 
oesophageal cancer death (HR = 0.67; 95% CI: 0.42–1.08), and for all alcohol-related cancer deaths 
(HR = 0.64; 95% CI: 0.40–1.03). We did not find a significant association between the selected 
SNPs and recurrence or SPC. 
 
4. Discussion 
 
We evaluated the prognostic significance of demographics, alcohol and tobacco, clinical features 
and selected polymorphisms of genes ADH1B and ADH7 on overall survival, recurrence and 
occurrence of SPC in a large cohort of HNC patients. 
Our results show that 5-year overall survival was 62%, similar to that reported in a previous study 
[34]. Survival differed largely among HNC sites: as expected from previous studies, larynx cancers 
had the best and hypopharynx cancers had the worst prognosis [34]. 
Predictors of overall survival of HNC were older ages, higher tumour stage, and high alcohol 
consumption. Additionally, considering the specific HNC sites, a combined therapy including 
radiotherapy plus surgical treatment and chemotherapy, was a negative prognostic factor for oral 
cavity cancer. 
Several epidemiologic studies in different head and neck sites have examined the association 
between alcohol consumption prediagnosis and survival/increased risk of death, sometimes in a 
dose-dependent  fashion,  with  conflicting  results  [35–38].  A multicentric population-based case–
control study of laryngeal and hypopharyngeal cancer carried out in six European regions, reported 
that alcohol drinking affects the survival, albeit to a limited extent [36]. However, more recent 
studies that have examined the effect of alcohol drinking on survival reported opposite results 
[37,38]. 
Evidence is accruing that smoking may also be causally related with increased all-cause mortality. 
One study reported that the effect of smoking was evident only among the chemoradiotherapy or 
radiotherapy group [37]; another, found that smoking status was the strongest predictor of survival, 
in both current and former smokers [38]; a third large population-based study from Ireland, 
involving 5652 patients with HNC, reported significantly increased cancer-related death rate for 
current smokers with oral cavity, pharyngeal, and laryngeal cancers, and the association was 
stronger in surgically treated patients [39]. Moreover, the association between cigarette smoking 
and survival has been demonstrated also in colon [40], pancreatic cancer [41], renal cell carcinoma 
[42], oropharyngeal [43], and nasopharyngeal carcinoma [44] highlighting a possible enduring 
effects of smoking, even after stopping. 
In our study, smoking status at diagnosis is not an independent prognostic factor of overall survival 
among patients with HNC. One possible explanation for this is that current smokers will have been 
recorded as ex-smokers, which would mean that the true effect of smoking at diagnosis on mortality 
has been underestimated. 
In our study, cancer recurrence was associated with higher tumour stage of the disease and duration 
of cigarette smoke is a predictor of SPC. An extensive literature shows that the most frequent SPC 
sites after first HNC is HNC, lung and oesophagus as these are tobacco and alcohol related tumours 
[45–49], however there are conflicting results about the factors associated with the development of 
SPCs. Slaughter et al. [50] proposed the theory of field cancerization, where carcinogenic effects 
from tobacco and alcohol may act on multiple places of the aerodigestive tract mucosa, triggering 
the development of multiple lesions. Previous reports suggested that additional prognostic factors 
for SPC among HNC patients are older age, hypopharyngeal index tumour site, and heavy alcohol 
consumption among Asians [47]. 
We investigated the associations between ADH1B rs1229984 and ADH7 rs1573496 
polymorphisms with overall survival, recurrence, and SPC. Recent studies showed that SPC can 
share some genetic markers with the index tumours and that they can derive from the same 
genetically altered mucosal field as the primary tumour [51]. ADH1B, with ADH1A and AD1C, 
accounts for most of the ethanol oxidizing capacity in the liver, whereas the enzyme coded by 
ADH7 is active as a retinol dehydrogenase and its expression is much more abundant in stomach 
than liver. ADH1B rs1229984 and ADH7 rs1573496 variants were identified to be protective 
against aerodigestive cancer in European and Latin American populations [20]. A genome-wide 
association study conducted in two European case–control studies on upper aerodigestive tract 
cancer and further studies in a Chinese and Japanese population supported this association 
[30,52,53]. 
In  our study, ADH1B  rs1229984 polymorphism were not consistetly  related  with  HNC  and  
oesophageal  cancer  and alcohol-related cancer deaths. Moreover no influence on recurrence or 
SPC was observed. rs1229984 (ADH1B) G/T heterozygotes and T/T homozygotes are known to 
metabolize ethanol up to 40 times  quicker  than  the  common  rs1229984  (ADH1B)  G/G 
homozygote, providing support that quick eradication of ethanol, and therefore lower local exposure, 
may be protective also on the prognosis. The only study addressing such associations, however, did 
not report a protective effect of the aforementioned SNPs [14]. In interpreting our results some 
limitations should be acknowledged. Firstly, in the analysis of recurrence and SPC we were unable 
to stratify according to HNC site due to reduced power. 
Secondly, we did not have information on HPV status which is a well-known prognostic factor for 
oropharyngeal cancer [54]. Thirdly, information on tobacco smoking and on alcohol drinking after 
treatment of the index tumour, that might additionally influence SPC occurrence, was not collected. 
Results show that advanced age, tumour stage, and alcohol consumption were predictors of HNC 
survival. Predictors of recurrence was HNC stage, while SPC risk was associated with smoking 
duration. Lastly, the ADH1B rs1229984 polymorphism could be associated with a better prognosis. 
Additional studies including a larger set of HNC patients might provide insights into the prognostic 
factors for recurrence and SPC by cancer sites. Further SNPs of the ADH gene should be genotyped 
and analysed to completely capture the influence this family gene in the prognosis of HNC. 
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Table 1 
Characteristics of 801 cases of head and neck cancer in 5 Italian centres according to tumour site 
 
NOS: not otherwise specified 
 
Table 2 
Predictors of overall survival among 801 head and neck cancer (HNC) cases by tumour site by multivariable analysis 
 
 
Text in bold indicates statistically significant risk factors. 
HR: hazard ratio; CI: confidence interval; nc: not computable; TOT: total. 
HR adj: HR adjusted by age, gender, stage, comorbidity. In the multivariable analysis, cases from Milan centre excluded because information on 
tumour stage was not available. 
(#) More than 5% of the data were missing. 
(§) The three most common types of cancer treatment were reported. 10% (n = 83) of the information is missing 
 
Table 3 
Predictors of recurrence and second primary cancer among head and neck cancer cases from multivariable analyses 
 
 
Text in bold indicates statistically significant risk factors. HR: hazard ratio; CI: confidence interval. 
(#) More than 5% of the data were missing. 
(§) The three most common types of cancer treatment were reported. 10% (n = 83) of the information is missing. 
a  HR adjusted by age, stage. 
b  HR adjusted by age 
 
 
Table 4 
Effects of the alcohol dehydrogenase polymorphisms (ADH) rs1229984 and rs1573496 on head and neck cancer (HNC) 
prognosis 
 
SPC: second primary cancer; HR: hazard ratio; CI: confidence interval; TOT: total. 
 
 
 
Fig. 1 
Kaplan-Meier unadjusted overall 5-year survival by head and neck cancer site 
 
 
 
 
 
